

PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION

^{Pr}**NAT-TERIFLUNOMIDE**

Teriflunomide tablets

Tablets, 14 mg, Oral

Immunomodulator Agent

Natco Pharma (Canada) Inc.
2000 Argentia Road, Plaza 1, Suite 200
Mississauga, ON L5N 1P7

Date of Initial Authorization:
June 16, 2020

Date of Revision:
October 27, 2023

Submission Control Number: 278125

RECENT MAJOR LABEL CHANGES

7 WARNINGS AND PRECAUTIONS, Hepatic/Biliary/Pancreatic	10/2023
7 WARNINGS AND PRECAUTIONS, Respiratory	10/2023
7 WARNINGS AND PRECAUTIONS, 7.1 Special Populations, 7.1.1 Pregnant Women	05/2022
7 WARNINGS AND PRECAUTIONS, 7.1 Special Populations, 7.1.3 Pediatrics	10/2023

TABLE OF CONTENTS

Sections or subsections that are not applicable at the time of authorization are not listed.

RECENT MAJOR LABEL CHANGES	2
TABLE OF CONTENTS	2
PART I: HEALTH PROFESSIONAL INFORMATION	4
1 INDICATIONS	4
1.1 Pediatrics.....	4
1.2 Geriatrics.....	4
2 CONTRAINDICATIONS	4
3 SERIOUS WARNINGS AND PRECAUTIONS BOX	5
4 DOSAGE AND ADMINISTRATION	5
4.1 Dosing Considerations	5
4.2 Recommended Dose and Dosage Adjustment	5
4.5 Missed Dose	6
5 OVERDOSAGE	6
6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING	6
7 WARNINGS AND PRECAUTIONS	7
7.1 Special Populations	14
7.1.1 Pregnant Women	14
7.1.2 Breast-feeding	15
7.1.3 Pediatrics	15
7.1.4 Geriatrics	15
8 ADVERSE REACTIONS	15
8.1 Adverse Reaction Overview	15
8.2 Clinical Trial Adverse Reactions	15
8.4 Abnormal Laboratory Findings: Hematologic, Clinical Chemistry and Other Quantitative Data	19

8.5	Post-Market Adverse Reactions.....	19
9	DRUG INTERACTIONS.....	20
9.2	Drug Interactions Overview	20
9.4	Drug-Drug Interactions	20
9.5	Drug-Food Interactions	24
9.6	Drug-Herb Interactions	24
9.7	Drug-Laboratory Test Interactions.....	24
10	CLINICAL PHARMACOLOGY	24
10.1	Mechanism of Action	24
10.2	Pharmacodynamics.....	24
10.3	Pharmacokinetics.....	25
11	STORAGE, STABILITY AND DISPOSAL.....	27
PART II: SCIENTIFIC INFORMATION		28
13	PHARMACEUTICAL INFORMATION.....	28
14	CLINICAL TRIALS.....	28
14.1	Clinical Trial by Indication	28
14.3	Comparative Bioavailability Studies.....	33
15	MICROBIOLOGY	33
16	NON-CLINICAL TOXICOLOGY	33
17	SUPPORTING PRODUCT MONOGRAPHS.....	35
PATIENT MEDICATION INFORMATION		36

PART I: HEALTH PROFESSIONAL INFORMATION

1 INDICATIONS

NAT-TERIFLUNOMIDE (teriflunomide) is indicated for:

- monotherapy for the treatment of patients with relapsing remitting multiple sclerosis (RRMS) to reduce the frequency of clinical exacerbations and to delay the accumulation of physical disability.

NAT-TERIFLUNOMIDE should only be prescribed by clinicians who are experienced in the diagnosis and management of multiple sclerosis.

1.1 Pediatrics

Pediatrics (< 18 years of age): The safety and efficacy of teriflunomide tablets have not been established in pediatric patients and NAT-TERIFLUNOMIDE is not recommended in this patient population.

1.2 Geriatrics

Clinical studies of teriflunomide did not include patients over 65 years old. NAT-TERIFLUNOMIDE should be used with caution in patients aged 65 years and over. Physicians who choose to treat geriatric patients should consider that treatment with NAT-TERIFLUNOMIDE in the context of a greater frequency of other concomitant diseases and concomitant drug therapy warrants caution and may necessitate additional or more frequent monitoring (see 7 WARNINGS AND PRECAUTIONS, 7.1 Special Populations, 7.1.4 Geriatrics).

2 CONTRAINDICATIONS

NAT-TERIFLUNOMIDE (teriflunomide) is contraindicated in patients:

- with known hypersensitivity to teriflunomide, leflunomide (the parent compound) or to any of the nonmedicinal ingredients in the formulation.
- who are currently treated with leflunomide.
- Co-administration of teriflunomide with leflunomide is contraindicated.
- with severe hepatic impairment (see 7 WARNINGS AND PRECAUTIONS, Hepatic/ Biliary/Pancreatic).
- who are pregnant or women of childbearing potential not using reliable contraception (see 7 WARNINGS AND PRECAUTIONS, Reproductive Health: Female and Male Potential). NAT-TERIFLUNOMIDE may cause fetal harm when administered to a pregnant woman. Pregnancy must be excluded before start of treatment.
- with immunodeficiency states (e.g. AIDS).
- with impaired bone marrow function or significant anemias, leucopenia, neutropenia or thrombocytopenia.
- with serious active infections.

3 SERIOUS WARNINGS AND PRECAUTIONS BOX

Serious Warnings and Precautions

Hepatotoxicity

Severe liver injury including fatal liver failure occurred rarely in the post marketing setting. Concomitant use of NAT-TERIFLUNOMIDE with other potentially hepatotoxic drugs may increase the risk of severe liver injury. Obtain transaminase and bilirubin levels within 6 months before initiation of NAT-TERIFLUNOMIDE therapy. Monitor ALT levels at least monthly for at least six months after starting NAT-TERIFLUNOMIDE (see 7 WARNINGS AND PRECAUTIONS, Hepatic/ Biliary/Pancreatic). If drug induced liver injury is suspected, discontinue NAT-TERIFLUNOMIDE and start an accelerated elimination procedure with cholestyramine or charcoal (see 7 WARNINGS AND PRECAUTIONS, Accelerated Elimination Procedure). NAT-TERIFLUNOMIDE is contraindicated in patients with severe hepatic impairment. Patients with pre-existing liver disease may be at increased risk of developing elevated serum transaminases when taking NAT-TERIFLUNOMIDE.

Risk of Teratogenicity

Based on animal data, TERIFLUNOMIDE may cause major birth defects if used during pregnancy. Pregnancy must be excluded before starting NAT-TERIFLUNOMIDE. NAT-TERIFLUNOMIDE is contraindicated in pregnant women or women of childbearing potential who are not using reliable contraception. Pregnancy must be avoided during NAT-TERIFLUNOMIDE treatment or prior to the completion of an accelerated elimination procedure after NAT-TERIFLUNOMIDE treatment (see 2 CONTRAINDICATIONS, 7 WARNINGS AND PRECAUTIONS, Reproductive Health: Female and Male Potential, Accelerated Elimination Procedure and 7.1 Special Populations, 7.1.1 Pregnant Women).

4 DOSAGE AND ADMINISTRATION

4.1 Dosing Considerations

Monitoring recommended prior to initiating and during treatment:

Obtain transaminase and bilirubin levels within 6 months before initiation of NAT-TERIFLUNOMIDE therapy. Monitor ALT levels at least monthly for at least six months after starting NAT-TERIFLUNOMIDE (see 7 WARNINGS AND PRECAUTIONS, Hepatic/ Biliary/Pancreatic).

Obtain a complete blood cell count (CBC) within 6 months before the initiation of treatment with NAT-TERIFLUNOMIDE and periodically during treatment. Further monitoring should be based on signs and symptoms of infection (see 7 WARNINGS AND PRECAUTIONS, Hematologic).

Prior to initiating NAT-TERIFLUNOMIDE, screen patients for latent tuberculosis infection (see 7 WARNINGS AND PRECAUTIONS, Immune - Infections).

Check blood pressure before start of NAT-TERIFLUNOMIDE treatment and periodically throughout treatment (see 7 WARNINGS AND PRECAUTIONS, Cardiovascular).

- Obtain a negative pregnancy test before initiation of treatment with NAT-TERIFLUNOMIDE (see 7 WARNINGS AND PRECAUTIONS, 7.1 Special Populations, 7.1.1 Pregnant Women).

4.2 Recommended Dose and Dosage Adjustment

The recommended dose of NAT-TERIFLUNOMIDE is 14 mg orally once daily which can be taken with or

without food.

Pediatric patients

The safety and efficacy of teriflunomide have not been established in pediatric patients and NAT-TERIFLUNOMIDE is not recommended in this patient population.

Geriatric patients

Clinical studies of teriflunomide did not include patients over 65 years old. NAT-TERIFLUNOMIDE should be used with caution in patients aged 65 years and overdue the greater frequency of other concomitant diseases and concomitant drug therapy (see 2 CONTRAINDICATIONS, 7 WARNINGS AND PRECAUTIONS, 7.1 Special Populations, 7.1.4 Geriatrics, 10 CLINICAL PHARMACOLOGY, 10.3 Pharmacokinetics, Special Populations and Conditions).

Hepatic impairment

No dosage adjustment is necessary for patients with mild and moderate hepatic impairment. Teriflunomide is contraindicated in patients with severe hepatic impairment (see 2 CONTRAINDICATIONS, 7 WARNINGS AND PRECAUTIONS, Hepatic/ Biliary/Pancreatic and).

Renal impairment

No dosage adjustment is necessary for patients with severe renal impairment (see 7 WARNINGS AND PRECAUTIONS, Renal).

Patients with severe renal impairment undergoing dialysis were not evaluated. Teriflunomide is not recommended in this population.

4.5 Missed Dose

If a dose is missed, treatment should be continued with the next dose as planned.

5 OVERDOSAGE

There is no experience regarding teriflunomide symptomatic overdose or intoxication in humans.

Teriflunomide 70 mg daily up to 14 days was well tolerated by healthy subjects.

In the event of relevant overdose or toxicity, cholestyramine or activated charcoal is recommended to accelerate elimination (see 7 WARNINGS AND PRECAUTIONS, General, Accelerated Elimination Procedure).

For management of a suspected drug overdose, contact your regional poison control centre.

6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING

Table – Dosage Forms, Strengths, Composition and Packaging

Route of Administration	Dosage Form / Strength/Composition	Non-medicinal Ingredients
Oral	Film-coated tablet/14 mg	Lactose monohydrate, pregelatinized starch, hydroxypropylcellulose, sodium starch glycolate, colloidal silicon dioxide, magnesium stearate, hypromellose, titanium dioxide, talc,

Route of Administration	Dosage Form / Strength/Composition	Non-medicinal Ingredients
		macrogol, indigo carmine aluminum lake.

NAT-TERIFLUNOMIDE is available in film-coated tablets containing 14 mg of teriflunomide: pale blue to pastel blue, pentagonal film-coated tablets debossed with “T14” on one side and plain on the other side.

NAT-TERIFLUNOMIDE is supplied as:

- Carton of 14 tablets of 14 mg containing 2 blister of 7 tablets
- Carton of 28 tablets of 14 mg containing 4 blisters of 7 tablets
- Carton of 84 tablets of 14 mg containing 12 blisters of 7 tablets
- HDPE bottles of 90 tablets of 14 mg.

7 WARNINGS AND PRECAUTIONS

Please see 3 SERIOUS WARNINGS AND PRECAUTIONS BOX.

General

Accelerated Elimination Procedure

Teriflunomide is eliminated slowly from the plasma.

Without an accelerated elimination procedure, it takes on average 8 months to reach plasma concentrations less than 0.02 mg/L, however, due to individual variations in drug clearance it may take as long as 2 years. An accelerated elimination procedure could be used at any time after discontinuation of NAT-TERIFLUNOMIDE.

Elimination can be accelerated by either of the following procedures:

- Administration of cholestyramine 8 g every 8 hours for 11 days. If cholestyramine 8 g three times a day is not well tolerated, cholestyramine 4 g three times a day can be used.
- Administration of 50 g oral activated charcoal powder every 12 hours for 11 days.

If either elimination procedure is poorly tolerated, treatment days do not need to be consecutive unless there is a need to lower teriflunomide plasma concentration rapidly.

At the end of 11 days, both regimens successfully accelerated teriflunomide elimination, leading to more than 98% decrease in teriflunomide plasma concentrations.

Use of the accelerated elimination procedure may potentially result in a gradual return of disease activity if the patient had been responding to NAT-TERIFLUNOMIDE treatment.

Both cholestyramine and activated powdered charcoal may interact with the absorption of some concomitant medications. In particular, it can influence the absorption of oestrogens and progestogens such that reliable contraception with oral contraceptives may not be guaranteed during the accelerated elimination procedure with cholestyramine or activated charcoal. Use of alternative contraceptive method is recommended.

Lactose

Because NAT-TERIFLUNOMIDE tablets contain lactose, patients with rare hereditary problems of galactose intolerance, lactase deficiency or glucose-galactose malabsorption, should not take NAT-TERIFLUNOMIDE.

Cardiovascular

In the multiple sclerosis placebo-controlled studies, mean change from baseline to endpoint value in systolic blood pressure was 2.6 mmHg for teriflunomide 14 mg, and -0.8 mmHg for placebo. The change from baseline in diastolic blood pressure was 1.8 mmHg for teriflunomide 14 mg and -0.5 mmHg for placebo.

Hypertension was reported as an adverse reaction in 4.2% of patients treated with 14 mg of teriflunomide, compared with 2% on placebo for up to 2 years in the placebo-controlled trials. During a long-term extension safety study, new onset hypertension was reported as a treatment emergent adverse event in 13.4% of patients overall who were treated with teriflunomide 14 mg for a median duration of approximately 5 years. At each 6-month interval during long-term treatment, treatment emergent adverse events of new onset hypertension were reported in up to 3% of patients treated with teriflunomide. Check blood pressure before the initiation of treatment with NAT-TERIFLUNOMIDE and periodically throughout treatment. Elevated blood pressure should be appropriately managed during treatment with NAT-TERIFLUNOMIDE.

Hematologic

A mean decrease in white blood cell (WBC) count of approximately 15% (mainly neutrophils and lymphocytes) and in platelet count of approximately 10% was observed in placebo-controlled trials with teriflunomide as compared to baseline. The decrease in mean WBC count occurred during the first 6 weeks and WBC count remained at the decreased level during treatment (see 8 ADVERSE REACTIONS).

The majority of patients recovered from decreased neutrophils and/or lymphocyte cell counts in less than 8 weeks, whether continuing on teriflunomide or after discontinuation.

Rare cases of pancytopenia, agranulocytosis and thrombocytopenia have been reported in the postmarketing setting with leflunomide. A similar risk is expected for teriflunomide.

Obtain a complete blood cell count (CBC) within 6 months before initiating treatment with NAT-TERIFLUNOMIDE and periodically during treatment. Further monitoring should be based on signs and symptoms suggestive of infection.

In any situation in which the decision is made to switch to or from teriflunomide, from or to another agent with a known potential for hematologic suppression, monitoring for hematologic toxicity is recommended, because there will be overlap of systemic exposure to both compounds, due to the slow elimination from plasma of teriflunomide and some of the other therapies (eg, natalizumab, fingolimod). Use of an accelerated elimination procedure may decrease this risk when switching to another therapy, but may also potentially result in return of disease activity if the patient had been responding to NAT-TERIFLUNOMIDE treatment (see 10 CLINICAL PHARMACOLOGY, 10.3 Pharmacokinetics; 7 WARNINGS AND PRECAUTIONS, Accelerated Elimination Procedure).

In patients with pre-existing anemia, leucopenia, and/or thrombocytopenia as well as in patients with impaired bone marrow function or those at risk of bone marrow suppression, the risk of hematological disorders is increased. If such effects occur, the accelerated elimination procedure should be considered.

Hepatic/ Biliary/Pancreatic

Hepatic:

Liver function abnormalities have been reported in some patients treated with teriflunomide in clinical trials. Severe liver injury including fatal liver failure occurred rarely in the post marketing setting. Patients with pre-existing liver disease may be at increased risk of developing elevated serum transaminases when taking teriflunomide. Patients with pre-existing acute or chronic liver disease, or those with serum alanine aminotransferase (ALT) greater than two times the upper limit of normal (ULN) before initiating treatment, should not normally be treated with teriflunomide. NAT-TERIFLUNOMIDE is contraindicated in patients with severe hepatic impairment (see 2 CONTRAINDICATIONS).

Elevations of liver enzymes have been observed in patients receiving teriflunomide.

In placebo-controlled trials, ALT greater than three times the ULN occurred in 44/786 (5.6%) of patients on teriflunomide 14 mg and 30/806 (3.7%) of patients on placebo, during the treatment period of up to 2 years. These elevations occurred mostly within the first 6 months of treatment. Half of the cases returned to normal without drug discontinuation. In clinical trials, teriflunomide was discontinued if the ALT elevation exceeded 3 times the ULN on two consecutive tests.

Of the patients who underwent discontinuation of teriflunomide and accelerated elimination in controlled trials, serum transaminase levels returned to normal within approximately 2 months.

In controlled clinical trials, one serious case of “toxic hepatitis” was reported in a 35-year-old female patient. The patient developed ALT 32 times the ULN and jaundice 5 months after initiation of teriflunomide 14 mg treatment. The patient was hospitalized for 5 weeks and recovered after plasmapheresis and cholestyramine accelerated elimination procedure. Although the etiology of the hepatic event remained unclear, a causal role of teriflunomide in this case is possible.

Cases of drug-induced liver injury (DILI) have been observed in the post-marketing setting, sometimes life-threatening (see 8 ADVERSE REACTIONS, 8.5 Post-Market Adverse Reactions). The time to onset of DILI ranged from days to years after initiating treatment with teriflunomide. Drug-induced liver injury events were reported in patients with and without relevant risk factors, such as a history of drug-induced hepatotoxicity or concomitant use of other hepatotoxic drugs, including some drugs used for managing multiple sclerosis. Due to the potential for severe liver injury, exercise caution and closely monitor patients if other known or potentially hepatotoxic drugs are used in combination with teriflunomide or if there is a history of drug-induced hepatotoxicity (see 3 SERIOUS WARNINGS AND PRECAUTIONS BOX, Hepatotoxicity and Risk of Teratogenicity).

For all patients, obtain serum transaminase and bilirubin levels within 6 months before initiating treatment with teriflunomide. Monitor ALT levels at least monthly for at least six months after starting NAT-TERIFLUNOMIDE. Additional monitoring is recommended if NAT-TERIFLUNOMIDE is used with other potentially hepatotoxic drugs or if there is a history of drug-induced hepatotoxicity. Consider discontinuing NAT-TERIFLUNOMIDE if serum transaminase increase (greater than three times the ULN) is confirmed. Monitor serum transaminase and bilirubin on NAT-TERIFLUNOMIDE therapy, particularly in patients who develop symptoms suggestive of hepatic dysfunction, such as unexplained nausea, vomiting, abdominal pain, fatigue, anorexia, or jaundice and/or dark urine. Patients should be advised to immediately report signs or symptoms of hepatotoxicity. If liver injury is suspected to be teriflunomide-induced, discontinue NAT-TERIFLUNOMIDE and start an accelerated elimination procedure (see 7 WARNINGS AND PRECAUTIONS, General, Accelerated Elimination Procedure) and monitor liver tests weekly until normalized. If teriflunomide-induced liver injury is unlikely because

some other probable cause has been found, resumption of teriflunomide therapy may be considered.

Due to a potential for additive hepatotoxic effects, alcohol consumption should be avoided during treatment with NAT-TERIFLUNOMIDE.

Hypoproteinemia

Since teriflunomide is highly protein bound and as the binding is dependent upon the concentrations of albumin, unbound plasma teriflunomide concentrations are expected to be increased in patients with hypoproteinemia, e.g. in nephrotic syndrome. Teriflunomide is not recommended in patients with conditions of severe hypoproteinemia.

Hepatic Impairment:

NAT-TERIFLUNOMIDE is contraindicated in patients with severe hepatic impairment (see 2 CONTRAINDICATIONS, 7 WARNINGS AND PRECAUTIONS, Hepatic/ Biliary/Pancreatic). Mild and moderate hepatic impairment had no impact on the pharmacokinetics of teriflunomide. No dosage adjustment is anticipated for patients with mild and moderate hepatic impairment.

Pancreatitis:

Very rare cases of acute symptomatic pancreatitis with no alternative etiologies, have been reported during treatment with teriflunomide in adult MS patients (see 8 ADVERSE REACTIONS, 8.5 Post-Market Adverse Reactions).

In a clinical trial of pediatric MS patients the frequency of pancreatitis was higher in patients treated with teriflunomide than in patients that received placebo and, higher than what has been observed in adult MS patients (see 8.2 Clinical Trial Adverse Reactions, Pediatric population).

For patients with symptoms of acute pancreatitis that are suspected to be teriflunomide-induced, discontinue NAT-TERIFLUNOMIDE and start an accelerated elimination procedure (see 7 WARNINGS AND PRECAUTIONS, General, Accelerated Elimination Procedure).

Immune

Infections:

Patients with active acute or chronic infections should not start treatment until the infection(s) is resolved. If a patient develops a serious infection during treatment, consider suspending treatment with NAT-TERIFLUNOMIDE and using an accelerated elimination procedure (see 7 WARNINGS AND PRECAUTIONS, General, Accelerated Elimination Procedure). Reassess the benefits and risks prior to resumption of therapy. Instruct patients receiving NAT-TERIFLUNOMIDE to report symptoms of infections to a physician.

NAT-TERIFLUNOMIDE is contraindicated in patients with severe immunodeficiency, bone marrow disease, or severe, uncontrolled infections (see 2 CONTRAINDICATIONS). Medications like teriflunomide that have immunomodulatory potential may cause patients to be more susceptible to infections, including opportunistic infections.

In placebo-controlled studies of teriflunomide, no overall increase in the risk of serious infections was observed with teriflunomide 14 mg 2.5% compared to placebo 2.5%. However, one fatal case of *klebsiella pneumonia* sepsis occurred in a patient taking teriflunomide 14 mg for 1.7 years. In clinical studies with teriflunomide, cytomegalovirus hepatitis reactivation has been observed. Fatal infections, especially *Pneumocystis jiroveci* pneumonia and aspergillosis, have been reported in the postmarketing setting, in patients receiving leflunomide for treatment of rheumatoid arthritis. Most of the reports

were confounded by concomitant immunosuppressant therapy and/or comorbid illness which, in addition to rheumatoid disease, may predispose patients to infection.

In clinical studies with teriflunomide, cases of tuberculosis have been observed. Prior to initiating NAT-TERIFLUNOMIDE, screen patients for latent tuberculosis infection. The safety of teriflunomide in individuals with latent tuberculosis infection is unknown, as tuberculosis screening was not systematically performed in clinical studies. For patients testing positive in tuberculosis screening, treat by standard medical practice prior to initiating treatment with NAT-TERIFLUNOMIDE.

Hypersensitivity:

Cases of hypersensitivity, angioedema and anaphylactic reaction have been reported during the post-marketing period (see 8 ADVERSE REACTIONS, 8.5 Post-Market Adverse Reactions).

Advise the patient to discontinue NAT-TERIFLUNOMIDE and seek immediate medical care if any signs or symptoms of anaphylaxis or angioedema occurs.

Concomitant use of Immunosuppressive or Immunomodulating Therapies:

As leflunomide is the parent compound of teriflunomide, co-administration of NAT-TERIFLUNOMIDE with leflunomide is contraindicated.

Co-administration with antineoplastic or immunosuppressive therapies has not been evaluated and is not recommended due to the potential risk of additive immune system effects.

Switching to or from NAT-TERIFLUNOMIDE:

Based on the clinical data related to concomitant administration of teriflunomide with interferon beta or with glatiramer acetate, no waiting period is required when initiating NAT-TERIFLUNOMIDE after interferon beta or glatiramer acetate or when starting interferon beta or glatiramer acetate after NAT-TERIFLUNOMIDE.

For switches to or from natalizumab or fingolimod see 7 WARNINGS AND PRECAUTIONS, Hematologic.

Due to the characteristics and duration of alemtuzumab immune suppressive effects, initiating treatment with NAT-TERIFLUNOMIDE after alemtuzumab is not recommended unless the benefits of NAT-TERIFLUNOMIDE treatment clearly outweigh the risks for the individual patient.

Vaccination:

Two clinical studies have shown that teriflunomide treated patients mounted appropriate immune responses when vaccinated with inactivated neoantigen (first vaccination), or recall antigen (reexposure). No clinical data are available on the efficacy and safety of live vaccinations in patients taking teriflunomide. Vaccination with live vaccines is, however, not recommended. The long half-life of NAT-TERIFLUNOMIDE should be considered when contemplating administration of a live vaccine after stopping NAT-TERIFLUNOMIDE.

Monitoring and Laboratory Tests

- Check blood pressure before initiation of treatment with NAT-TERIFLUNOMIDE and periodically throughout treatment. Blood pressure should be appropriately managed during treatment with NAT-TERIFLUNOMIDE.
- Obtain a complete blood cell (CBC) count before initiation of treatment with NAT-TERIFLUNOMIDE and periodically during treatment. Further monitoring should be based on signs and symptoms suggestive of infection.
- Obtain serum transaminases and bilirubin levels within 6 months before initiation of treatment

with NAT-TERIFLUNOMIDE. Monitor ALT levels at least monthly for at least six months after starting NAT-TERIFLUNOMIDE.

- Obtain a negative pregnancy test before initiation of treatment with NAT-TERIFLUNOMIDE.

Neurologic

Peripheral Neuropathy:

In placebo-controlled studies, peripheral neuropathy, including both polyneuropathy and mononeuropathy (e.g., carpal tunnel syndrome), was reported more frequently in patients taking teriflunomide than in patients taking placebo. In the pivotal, placebo-controlled studies, the incidence of peripheral neuropathy confirmed by nerve conduction studies was 2.2% (15 patients out of 685) on 14 mg of teriflunomide, compared with 0.6% (4 patients out of 708) on placebo. Treatment was discontinued in 2 patients with confirmed peripheral neuropathy on 14 mg of teriflunomide; one of them recovered following treatment discontinuation. The other case of peripheral neuropathy did not resolve with continued treatment. There have also been reports of peripheral neuropathy in patients receiving leflunomide.

Age older than 60 years, concomitant neurotoxic medications, and diabetes may increase the risk for peripheral neuropathy. If a patient taking NAT-TERIFLUNOMIDE develops symptoms consistent with peripheral neuropathy, such as bilateral numbness or tingling of hands or feet, consider discontinuing NAT-TERIFLUNOMIDE therapy and performing an accelerated elimination procedure (see 7 WARNINGS AND PRECAUTIONS, General, Accelerated Elimination Procedure).

Renal

Severe renal impairment had no impact on the pharmacokinetics of teriflunomide. No dosage adjustment is necessary for patients with severe renal impairment.

Patients with severe renal impairment undergoing dialysis were not evaluated. NAT-Teriflunomide is not recommended in this population.

Reproductive Health: Female and Male Potential

- **Teratogenic Risk**

Use in Women of Childbearing Potential:

NAT-TERIFLUNOMIDE is contraindicated in women who are pregnant or women of child bearing potential not using reliable contraception. If the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to a fetus. If pregnancy does occur during treatment, the drug should be immediately discontinued and an accelerated elimination procedure should be initiated (see 7 WARNINGS AND PRECAUTIONS, General, Accelerated Elimination Procedure). Under these conditions, the patient should be referred to an obstetrician/gynecologist, preferably experienced in reproductive toxicity, for further evaluation and counseling.

There are no adequate and well-controlled studies of teriflunomide in pregnant women.

However, based on animal studies, teriflunomide may increase the risk of fetal death or teratogenic effects when administered to pregnant women (see 16 NON-CLINICAL TOXICOLOGY, Reproductive and Developmental Toxicology). In animal studies, teriflunomide has been shown to be selectively teratogenic and embryolethal in multiple species when administered during pregnancy at doses less than those used clinically.

Women of childbearing potential must not be started on NAT-TERIFLUNOMIDE until pregnancy is

excluded and it has been confirmed that they are using reliable contraception (see 2 CONTRAINDICATIONS). Before starting treatment with NAT-TERIFLUNOMIDE, patients must be fully counseled on the potential for serious risk to the fetus (see 3 SERIOUS WARNINGS AND PRECAUTIONS BOX, Hepatotoxicity and Risk of Teratogenicity). The patient must be advised that if there is any delay in onset of menses or any other reason to suspect pregnancy, they must notify the physician immediately for pregnancy testing and, if positive, the physician and patient must discuss the risk to the fetus.

Upon discontinuing NAT-TERIFLUNOMIDE, it is recommended that all women of childbearing potential not using reliable contraception undergo an accelerated elimination procedure (see 7 WARNINGS AND PRECAUTIONS, General, Accelerated Elimination Procedure). Women receiving NAT-TERIFLUNOMIDE treatment who wish to become pregnant must discontinue NAT-TERIFLUNOMIDE and undergo an accelerated elimination procedure, which includes verification that teriflunomide plasma concentrations decrease to at least 0.02 mg/L. Human plasma concentrations of teriflunomide less than 0.02 mg/L are expected to have minimal risk.

NAT-TERIFLUNOMIDE can increase the plasma concentration of oral contraceptives 1.54-fold, therefore consideration should be given to the type or dose of oral contraceptives used (see 9 DRUG INTERACTIONS).

Use in males:

Teriflunomide is detected in human semen. Animal studies to specifically evaluate the risk of male-mediated fetal toxicity have not been conducted. To minimize any possible risk, men not wishing to father a child and their female partners should use reliable contraception. Men wishing to father a child should discontinue use of NAT-TERIFLUNOMIDE and undergo an accelerated elimination procedure (see 7 WARNINGS AND PRECAUTIONS, General, Accelerated Elimination Procedure) to decrease the plasma concentration of teriflunomide to less than 0.02 mg/L.

Respiratory

Interstitial lung disease (ILD), including acute interstitial pneumonitis, has been reported with teriflunomide in the post marketing setting.

ILD and worsening of interstitial lung disease have been reported during treatment with leflunomide, the parent compound of teriflunomide. ILD is a potentially fatal disorder and may occur acutely at any time during treatment with a variable clinical presentation. The risk is increased in patients with a history of ILD.

Serious cases of pulmonary hypertension, some with a fatal outcome, have been reported with teriflunomide in the post marketing setting (see 8 ADVERSE REACTIONS, 8.5 Post-Market Adverse Reactions). The time to onset of pulmonary hypertension ranged from days to years after initiating treatment with teriflunomide. In several cases the patients had underlying hypertension, pulmonary hypertension, pulmonary embolism, or ILD.

New onset or worsening of pulmonary symptoms, such as persistent cough and dyspnea, with or without associated fever, may be a reason for discontinuation of the therapy and for further investigation, as appropriate. If discontinuation of the drug is necessary, consider initiation of an accelerated elimination procedure (see 7 WARNINGS AND PRECAUTIONS, General, Accelerated Elimination Procedure).

Skin

Severe cutaneous adverse reactions (SCARs)

Cases of serious skin reactions, sometimes fatal, including Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and drug reaction with eosinophilia and systemic symptoms (DRESS), have been reported in the postmarketing setting in patients treated with teriflunomide for MS.

If skin and/or mucosal reactions (ulcerative stomatitis) are observed which raise the suspicion of severe generalised major skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis, or drug reaction with eosinophilia and systemic symptoms), NAT-TERIFLUNOMIDE must be discontinued, and an accelerated elimination procedure initiated immediately (see 7 WARNINGS AND PRECAUTIONS, General, Accelerated Elimination Procedure). In such cases patients should not be re-exposed to NAT-TERIFLUNOMIDE (see 2 CONTRAINDICATIONS).

New onset of psoriasis (including pustular psoriasis) and worsening of pre-existing psoriasis have been reported during use of teriflunomide. Discontinuation of treatment and initiation of an accelerated elimination procedure may be considered, taking into account the patient's disease and medical history (see 8 ADVERSE REACTIONS, 8.5 Post-Market Adverse Reactions).

7.1 Special Populations

7.1.1 Pregnant Women

NAT-TERIFLUNOMIDE is contraindicated for pregnant women or women of childbearing age not using reliable contraception (see 2 CONTRAINDICATIONS and 7 WARNINGS AND PRECAUTIONS, Reproductive Health: Female and Male Potential).

There are no adequate and well-controlled studies of teriflunomide in pregnant women.

However, based on animal studies, teriflunomide may increase the risk of fetal death or teratogenic effects when administered to pregnant women (see 16 NON-CLINICAL TOXICOLOGY, Reproductive and Developmental Toxicology).

Women of childbearing potential must not be started on NAT-TERIFLUNOMIDE until pregnancy is excluded and it has been confirmed that they are using reliable contraception. Before starting treatment with NAT-TERIFLUNOMIDE, patients must be fully counseled on the potential for serious risk to the fetus (see 7 WARNINGS AND PRECAUTIONS, Reproductive Health: Female and Male Potential).

Teriflunomide Enhanced Pharmacovigilance Pregnancy Active Surveillance Program

Patients who have become pregnant or suspect they could be pregnant while taking NAT-TERIFLUNOMIDE or up to two years after discontinuing NAT-TERIFLUNOMIDE treatment should contact their healthcare professional. An Enhanced Pharmacovigilance Pregnancy Active Surveillance Program has been established to collect information about the effect of teriflunomide exposure during pregnancy. Physicians are encouraged to enroll pregnant women in the Enhanced Pharmacovigilance Pregnancy Active Surveillance Program, or pregnant women may enroll themselves in the Enhanced Pharmacovigilance Pregnancy Active Surveillance Program by calling 1-800-296-9329 and can access the program details and educational materials at the following website – www.natcopharma.ca.

Labour and Delivery

There is no adequate information regarding the effects of NAT-TERIFLUNOMIDE on labour and delivery in pregnant women.

7.1.2 Breast-feeding

Animal studies have shown excretion of teriflunomide in breast milk.

It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from teriflunomide, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.

7.1.3 Pediatrics

Pediatrics (< 18 years of age): The safety and efficacy of teriflunomide have not been established in pediatric patients and NAT-TERIFLUNOMIDE is not recommended in this patient population (see 7 WARNINGS AND PRECAUTIONS, Hepatic/Biliary/Pancreatic; 8.2 Clinical Trial Adverse Reactions, Pediatric Population).

7.1.4 Geriatrics

Clinical studies of teriflunomide did not include patients over 65 years old. NAT-TERIFLUNOMIDE should be used with caution in patients aged 65 years and over. Physicians who choose to treat geriatric patients should consider that treatment with NAT-TERIFLUNOMIDE in the context of a greater frequency of other concomitant diseases and concomitant drug therapy warrants caution and may necessitate additional or more frequent monitoring.

8 ADVERSE REACTIONS

8.1 Adverse Reaction Overview

The following most common adverse reactions were reported with a frequency $\geq 10\%$ in the 14 mg teriflunomide group and a difference of $\geq 1\%$ as compared to placebo: alopecia, diarrhea, ALT increased, and nausea.

The safety findings during long-term treatment with teriflunomide were generally consistent with those reported during the 2-year placebo controlled clinical trials (see 8 ADVERSE REACTIONS, Long-term safety).

Teriflunomide is the main metabolite of leflunomide. The safety profile of leflunomide in patients suffering from rheumatoid arthritis may be pertinent when prescribing teriflunomide in MS patients.

8.2 Clinical Trial Adverse Reactions

Because clinical trials are conducted under very specific conditions the adverse reaction rates observed in the clinical trials may not reflect the rates observed in practice and should not be compared to the rates in the clinical trials of another drug. Adverse drug reaction information from clinical trials may be useful in identifying and approximating rates of adverse reaction in real-world use.

Adult

Placebo Controlled Trials

A total of 786 patients on teriflunomide 14 mg once daily and 806 on placebo constituted the safety population in the pooled analysis of placebo-controlled studies in patients with relapsing remitting

forms of MS (RRMS) (see 14 CLINICAL TRIALS).

Table 1 Adverse Reactions in Placebo controlled studies (occurring in $\geq 1\%$ of patients, and reported for teriflunomide 14 mg at $\geq 1\%$ higher rate than for placebo)

PRIMARY SYSTEM ORGAN CLASS Preferred Term (%)	Teriflunomide 14 mg (N=786)	Placebo (N=806)
INFECTIONS AND INFESTATIONS		
Influenza	72 (9.2%)	60 (7.4%)
Sinusitis	47 (6.0%)	31 (3.8%)
Gastroenteritis viral	23 (2.9%)	11 (1.4%)
Oral herpes	19 (2.4%)	10 (1.2%)
BLOOD AND LYMPHATIC SYSTEM DISORDERS		
Neutropenia	54 (6.9%)	13 (1.6%)
NERVOUS SYSTEM DISORDERS		
Paraesthesia	66 (8.4%)	57 (7.1%)
Carpal tunnel syndrome	16 (2.0%)	8 (1.0%)
VASCULAR DISORDERS		
Hypertension	33 (4.2%)	16 (2.0%)
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS		
Dyspnoea	13 (1.7%)	5 (0.6%)
GASTROINTESTINAL DISORDERS		
Diarrhoea	113 (14.4%)	63 (7.8%)
Nausea	97 (12.3%)	63 (7.8%)
Abdominal pain upper	44 (5.6%)	35 (4.3%)
Toothache	25 (3.2%)	15 (1.9%)
SKIN AND SUBCUTANEOUS TISSUE DISORDERS		
Alopecia	111 (14.1%)	35 (4.3%)
Rash	39 (5.0%)	27 (3.3%)

PRIMARY SYSTEM ORGAN CLASS Preferred Term (%)	Teriflunomide 14 mg (N=786)	Placebo (N=806)
MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS		
Musculoskeletal pain	28 (3.6%)	19 (2.4%)
RENAL AND URINARY DISORDERS		
Pollakiuria	16 (2.0%)	8 (1.0%)
REPRODUCTIVE SYSTEM AND BREAST DISORDERS		
Menorrhagia	12 (1.5%)	3 (0.4%)
INVESTIGATIONS		
Alanine aminotransferase increased	110 (14.0%)	62 (7.7%)
Aspartate aminotransferase increased	24 (3.1%)	10 (1.2%)
Weight decreased	21 (2.7%)	8 (1.0%)
Gamma-glutamyltransferase increased	18 (2.3%)	7 (0.9%)
Neutrophil count decreased	17 (2.2%)	8 (1.0%)
White blood cell count decreased	11 (1.4%)	2 (0.2%)

The most frequently reported (in > 1% of patients treated with teriflunomide) Treatment Emergent Adverse Events leading to discontinuation are neutropenia 8 (1%), alopecia 12 (1.5%) and alanine aminotransferase increased 14 (1.7%).

Cardiovascular deaths

Four cardiovascular deaths, including three sudden deaths, and one myocardial infarction in a patient with a history of hyperlipidemia and hypertension were reported among approximately 2600 patients exposed to teriflunomide in the premarketing database. These cardiovascular deaths occurred during uncontrolled extension studies, one to nine years after initiation of treatment. A relationship between teriflunomide and cardiovascular death has not been established.

Hypophosphatemia

In clinical trials, 17% of 14 mg teriflunomide-treated subjects had mild hypophosphatemia (≥ 0.6 mmol/L and < lower limit of normal), compared to 6% of placebo-treated subjects; 5% of 14 mg teriflunomide-treated subjects had moderate hypophosphatemia (≥ 0.3 mmol/L and <0.6 mmol/L),

compared to 1% of placebo-treated subjects. No subject on teriflunomide 14 mg had a serum phosphorus <0.3 mmol/L.

Mean changes from baseline in inorganic phosphorus over time showed an effect of teriflunomide compared to placebo. The decrease in inorganic phosphorus in the teriflunomide groups was apparent as early as Week 2. The mean inorganic phosphorus level with teriflunomide decreased steadily within the first 6 to 12 weeks and stabilized thereafter until the end of the study. At Week 12 the mean changes from baseline in inorganic phosphorus were -0.01 mmol/L, and -0.14 mmol/L on placebo, and 14 mg, respectively.

Alopecia

Alopecia was reported as hair thinning, decreased hair density, hair loss, associated or not with hair texture change, in 14.6% of patients treated with 14 mg teriflunomide versus 4.5% in patients treated with placebo. Most cases were described as diffuse or generalized over scalp (no complete hair loss reported) and occurred most often during the first 6 months and with resolution in 100 of 115 (87%) patients treated with teriflunomide 14 mg; with almost all cases resolving while on therapy. Discontinuation because of alopecia was 1.5% in the 14 mg teriflunomide group, versus, 0.1% in the placebo group.

Long-term safety

A long term extension of one of the placebo-controlled clinical trials (TEMPO) in patients with RRMS evaluated the safety of teriflunomide in patients treated with teriflunomide for an overall median treatment duration of approximately 5 years (maximum treatment duration approximately 8.5 years). The safety findings during long-term treatment with teriflunomide were generally consistent with those reported during the 2-year placebo controlled clinical trials (see 7 WARNINGS AND PRECAUTIONS, Monitoring and laboratory tests; 8 ADVERSE REACTIONS, Clinical Trial Adverse Reactions, Placebo Controlled Trials).

Pediatric Population

In a clinical trial that included pediatric MS patients, pancreatitis was observed in 1.8% (2/109) of patients that received teriflunomide compared to no patients (0/57) that received placebo; one of these cases was serious. Two additional cases of pancreatitis were reported during treatment with teriflunomide in the open-label phase of the study. Clinical symptoms included abdominal pain, nausea and/or vomiting. Serum amylase and lipase were elevated in these patients. The time to onset was approximately one to three years. All patients recovered or were recovering after treatment discontinuation and an accelerated elimination procedure (see 7 WARNINGS AND PRECAUTIONS General, Accelerated Elimination Procedure; 7 WARNINGS AND PRECAUTIONS, Hepatic/Biliary/Pancreatic).

The following adverse reactions were also reported more frequently in the pediatric MS clinical trial than in the adult MS clinical trials:

Alopecia was reported in 22.0% of patients treated with teriflunomide versus 12.3% in patients treated with placebo.

Infections were reported in 66.1% of patients treated with teriflunomide versus 45.6% in patients treated with placebo. Among them, nasopharyngitis and upper respiratory tract infections were reported more frequently with teriflunomide.

Creatine phosphokinase increase was reported in 5.5% of patients treated with teriflunomide versus 0% in patients treated with placebo. The majority of the cases were associated with documented

physical exercise.

Paraesthesia was reported in 11.0% of patients treated with teriflunomide versus 1.8% in patients treated with placebo.

Abdominal pain was reported in 11.0% of patients treated with teriflunomide versus 1.8% in patients treated with placebo.

8.4 Abnormal Laboratory Findings: Hematologic, Clinical Chemistry and Other Quantitative Data

Clinical Trial Findings

In placebo-controlled studies, neutrophil count $< 1.5 \times 10^9/L$ was observed in 16% of patients on teriflunomide 14 mg compared with 6% of patients on placebo; lymphocyte count $< 0.8 \times 10^9/L$ was observed in 11% of patients on teriflunomide 14 mg compared with 6% of patients on placebo.

Table 2 Abnormal Hematologic Results

	Teriflunomide 14 mg (N=786)	Placebo (N=806)
Neutrophil count < $1.5 \times 10^9/L$	125/783 (16%)	48/804 (6%)
Lymphocyte count < $0.8 \times 10^9/L$	88/783 (11%)	48/804 (6%)
Lymphocyte count < $0.5 \times 10^9/L$	19/783 (2.4%)	5/804 (0.6%)

8.5 Post-Market Adverse Reactions

In post-marketing experience with teriflunomide, the following adverse reactions have been identified:

Hypersensitivity reactions (see 7 WARNINGS AND PRECAUTIONS, Immune, Hypersensitivity)

Immediate or delayed, some of which were severe, such as anaphylaxis and angioedema

Skin and Subcutaneous Tissue Disorders (see 7 WARNINGS AND PRECAUTIONS, Skin)

- Severe skin reactions including toxic epidermal necrolysis (TEN), Stevens Johnson syndrome (SJS) and drug reaction with eosinophilia and systemic symptoms (DRESS)
- Psoriasis (including pustular psoriasis and nail psoriasis)
- Nail disorders

Respiratory, thoracic and mediastinal disorders (see 7 WARNINGS AND PRECAUTIONS, Respiratory)

- Interstitial lung disease (ILD)
- Pulmonary hypertension

Gastrointestinal Disorders (see 7 WARNINGS AND PRECAUTIONS Hepatic/Biliary/Pancreatic, Skin)

Stomatitis (such as aphthous or ulcerative)

- Pancreatitis in adult and pediatric patients
- Colitis

Hepatobiliary Disorders (see 3 SERIOUS WARNINGS AND PRECAUTIONS BOX, Hepatotoxicity and Risk of Teratogenicity and 7 WARNINGS AND PRECAUTIONS, Hepatic/ Biliary/Pancreatic)

Hepatic Disorders

- Liver failure
- Drug-induced liver injury (DILI)

Because these reactions are reported voluntarily from a population of uncertain size, it is not possible to reliably estimate their frequency.

9 DRUG INTERACTIONS

9.2 Drug Interactions Overview

The primary biotransformation pathway for teriflunomide is hydrolysis, with oxidation being a minor pathway, with limited involvement of cytochrome P450 (CYP) or flavin monoamine oxidase enzymes.

As leflunomide is the parent compound of teriflunomide, co-administration of teriflunomide with leflunomide is contraindicated.

Caution is recommended if NAT-TERIFLUNOMIDE is used in combination with other hepatotoxic drugs due to a potential for additive hepatotoxic effects or if NAT-TERIFLUNOMIDE is used in patients with a history of drug-induced hepatotoxicity (see 7 WARNINGS AND PRECAUTIONS, Hepatic/ Biliary/Pancreatic; 8 ADVERSE REACTIONS, 8.5 Post-Market Adverse Reactions).

Co-administration with antineoplastic or immunosuppressive therapies used for treatment of multiple sclerosis has not been evaluated and is not recommended due to the potential risk of additive immune system effects. Caution should also be exercised when switching patients to or from another agent with a known potential for hematologic suppression because there will be overlap of systemic exposure to both compounds (see 7 WARNINGS AND PRECAUTIONS, Hematologic).

9.4 Drug-Drug Interactions

Potential for other drugs to affect NAT-TERIFLUNOMIDE

Based on in vitro studies, teriflunomide is a substrate of the efflux transporter BCRP. BCRP inhibitors (such as cyclosporine, eltrombopag, gefitinib) may increase exposure of teriflunomide.

Rifampin did not affect the pharmacokinetics of teriflunomide.

Potential for NAT-TERIFLUNOMIDE to affect other drugs

The drugs listed in this table are based on either drug interaction case reports or studies, or potential interactions due to the expected magnitude and seriousness of the interaction (i.e., those identified as contraindicated).

Table 3 - Established or Potential Drug-Drug Interactions

Proper name	Source of Evidence	Effect	Clinical comment
CYP2C8 substrates	CT	Increase in drug concentration	<p>There was an increase in mean repaglinide C_{max} and AUC (1.64 - and 2.28-fold, respectively), following repeated doses of teriflunomide and a single dose of 0.25 mg repaglinide, suggesting that teriflunomide is an inhibitor of CYP2C8 in vivo.</p> <p>The magnitude of interaction could be higher at the recommended repaglinide dose. Therefore, monitoring patients with concomitant use of drugs metabolized by CYP2C8, such as repaglinide, paclitaxel, pioglitazone, or rosiglitazone is recommended as they may have higher exposure.</p>
Oral contraceptives	CT	Increase in drug concentration	<p>There was an increase in mean ethinylestradiol C_{max} and AUC_{0-24} (1.58- and 1.54-fold, respectively) and levonorgestrel C_{max} and AUC_{0-24} (1.33- and 1.41-fold, respectively) following repeated doses of teriflunomide.</p> <p>While this interaction of teriflunomide is not expected to adversely impact the efficacy of oral contraceptives, consideration should be given to the type or dose of oral contraceptives used in combination with teriflunomide.</p>

Proper name	Source of Evidence	Effect	Clinical comment
CYP1A2 substrates	CT	Decrease in drug concentration	<p>Repeated doses of teriflunomide decreased mean C_{max} and AUC of caffeine (CYP1A2 substrate) by 18% and 55 %, respectively, suggesting that in vivo teriflunomide is a weak inducer of CYP1A2.</p> <p>Therefore, drugs metabolized by CYP1A2 (such as duloxetine, theophylline and tizanidine) should be used with caution during treatment with teriflunomide, as it could lead to the reduction of efficacy of these drugs.</p>
Warfarin	CT	Decrease in INR	<p>A 25% decrease in peak international normalized ratio (INR) was observed when teriflunomide was co administered with warfarin as compared with warfarin alone. Therefore, when warfarin is co administered with teriflunomide, close INR follow-up and monitoring is recommended.</p>
CYP2B6, CYP3A, CYP2C9, CYP2C19 and CYP2D6 substrates	CT	No effect	<p>Teriflunomide did not affect the pharmacokinetics of bupropion (a CYP2B6 substrate), midazolam (a CYP3A substrate), S-warfarin (a CYP2C9 substrate), omeprazole (a CYP2C19 substrate) and metoprolol (a CYP2D6 substrate).</p>

Proper name	Source of Evidence	Effect	Clinical comment
Organic anion transporter (OAT) 3 substrates	CT	Increase in drug concentration	<p>There was an increase in mean cefaclor C_{max} and AUC (1.43- and 1.54-fold, respectively), following repeated doses of teriflunomide, suggesting that teriflunomide is an inhibitor of OAT3 in vivo.</p> <p>Therefore, when teriflunomide is co administered with substrates of OAT3, such as cefaclor, penicillin G, ciprofloxacin, indomethacin, ketoprofen, furosemide, cimetidine, methotrexate, zidovudine, caution should be observed.</p>
BCRP and /or organic anion transporting polypeptide (OATP) 1B1 and 1B3 substrates	CT		<p>There was an increase in mean rosuvastatin C_{max} and AUC (2.65- and 2.51-fold, respectively), following repeated doses of teriflunomide. However, there was no apparent impact of this increase in plasma rosuvastatin exposure on the HMG-CoA reductase activity. If used together, the dose of rosuvastatin should not exceed 10 mg once daily.</p> <p>For other substrates of BCRP (e.g., methotrexate, mitoxantrone, topotecan, sulfasalazine, daunorubicin, doxorubicin) and the OATP family, especially HMG-Co reductase inhibitors (e.g., simvastatin, atorvastatin pravastatin, methotrexate, nateglinide, repaglinide, rifampin), concomitant administration of teriflunomide should also be undertaken with caution. Monitor patients closely for signs and symptoms of excessive exposure to the drugs and consider reduction of the dose of these drugs.</p>

Legend: C = Case Study; CT = Clinical Trial; T = Theoretical

9.5 Drug-Food Interactions

Food does not have a clinically relevant effect on teriflunomide pharmacokinetics. Therefore, teriflunomide, once daily can be taken with or without food.

9.6 Drug-Herb Interactions

Interactions with herbal products have not been established.

9.7 Drug-Laboratory Test Interactions

Interactions with laboratory tests have not been established.

10 CLINICAL PHARMACOLOGY

10.1 Mechanism of Action

Teriflunomide is an immunomodulatory agent with anti-inflammatory properties that selectively and reversibly inhibits the mitochondrial enzyme dihydroorotate dehydrogenase (DHO-DH), required for the de novo pyrimidine synthesis. As a consequence teriflunomide blocks the proliferation of stimulated lymphocytes, which need de novo synthesis of pyrimidine to expand, may diminish the numbers of activated lymphocytes in peripheral blood. The exact mechanism by which teriflunomide exerts its therapeutic effect in MS is not known but may involve reduced numbers of activated lymphocytes available for migration into the central nervous system (CNS).

10.2 Pharmacodynamics

Potential to prolong the QT interval

In a placebo controlled thorough QT study performed in healthy subjects, teriflunomide at mean steady state concentrations did not show any potential for prolonging the QTcF interval compared with placebo.

Immune system

Effect on antibody response

In a clinical study, teriflunomide-treated patients mounted appropriate immune responses to a seasonal influenza vaccination. Patients achieved post-vaccination antibody titers, consistent with seroprotection. Also, the immunogenicity of rabies vaccine was assessed in a placebo-controlled study in healthy volunteers. This study showed that although the antibody levels (mean titers 15.2 IU/mL post vaccination) were well above the threshold for seroprotection (≥ 0.5 IU/mL) the immunologic response was decreased during treatment with teriflunomide. Compared to placebo, antibody titers in response to rabies vaccine were 47% lower in subjects receiving teriflunomide.

Effects on immune cell numbers in the blood

In the placebo-controlled studies, teriflunomide 14 mg once a day led to a mild mean reduction in lymphocyte count, of less than $0.3 \times 10^9/L$, which occurred over the first 3 months of treatment; these reductions were maintained until the end of the treatment.

Effect on renal tubular functions

In the placebo-controlled studies, mean decreases in serum uric acid at a range of 20 to 30% were observed in patients treated with teriflunomide compared to placebo.

Mean decrease in serum phosphorus was 10 to 15% in the teriflunomide group compared to placebo. These effects are considered to be related to increase in renal tubular excretion and not related to changes in glomerular functions.

10.3 Pharmacokinetics

Teriflunomide is the main active metabolite of leflunomide and is responsible for leflunomide's activity in vivo. At recommended doses, teriflunomide and leflunomide result in a similar range of plasma concentrations of teriflunomide.

Based on a population pharmacokinetic analysis of teriflunomide using data from healthy subjects and MS patients, median $t_{1/2z}$ was approximately 19 days after repeated doses of 14 mg. It takes approximately 3 months to reach steady-state concentrations. The estimated AUC accumulation ratio is approximately 30 after repeated doses of 14 mg.

Absorption

Median time to reach maximum plasma concentrations occurs between 1 to 4 hours post-dose following oral administration of teriflunomide. Food does not have a clinically relevant effect on teriflunomide pharmacokinetics.

Distribution

Teriflunomide is extensively bound to plasma protein (>99%), and is mainly distributed in plasma. The volume of distribution is 11 L after a single intravenous (IV) administration.

Metabolism

Teriflunomide is moderately metabolized and is the major circulating moiety detected in plasma. The primary biotransformation pathway to minor metabolites of teriflunomide is hydrolysis, with oxidation being a minor pathway. Secondary pathways involve oxidation, N-acetylation and sulfate conjugation.

Elimination

Teriflunomide was excreted in the gastrointestinal tract mainly through the bile as unchanged drug and possibly by direct secretion. The metabolites of teriflunomide are mainly excreted by the kidneys. Over 21 days, 60.1% of the administered dose was excreted via feces (37.5%) and urine (22.6%). After the accelerated elimination procedure with cholestyramine, an additional 23.1% was recovered (mostly in feces). After a single IV administration, the total body clearance of teriflunomide was 30.5 mL/h.

Accelerated Elimination Procedure: Cholestyramine and activated charcoal

Teriflunomide is eliminated slowly from the plasma. Without an accelerated elimination procedure, it takes on average 8 months to reach plasma concentrations less than 0.02 mg/L, but because of individual variations in drug clearance it may take as long as 2 years. An accelerated elimination procedure could be used at any time after discontinuation of NAT-TERIFLUNOMIDE (see 7 WARNINGS AND PRECAUTIONS, General, Accelerated Elimination Procedure). Use of the accelerated elimination procedure may potentially result in a gradual return of disease activity if the patient had been responding to teriflunomide treatment.

Special Populations and Conditions

- **Pediatrics**

The safety and efficacy of teriflunomide have not been established in pediatric patients and NAT-TERIFLUNOMIDE is not recommended in this patient population. In a clinical trial that included

pediatric patients aged 10 to 17, pancreatitis was reported more frequently in patients who received teriflunomide compared to those who received placebo (see 7 WARNINGS AND PRECAUTIONS, Hepatic/Biliary/Pancreatic; 8.2 Clinical Trial Adverse Reactions, Pediatric Population).

A population pharmacokinetic model was developed to describe the pharmacokinetics of teriflunomide in 135 pediatric patients with RRMS (10 to 17 years) once daily dosing.

Allometric scaling by body weight was used to describe the changes in the apparent oral clearance and distribution volumes of teriflunomide in the pediatric subjects. Overall exposures in pediatric patients weighing more than 40 kg were within the range of exposures in adult patients with RMS after 14 mg once daily; however, the median steady state AUC_{0-24} and C_{max} were about 17% higher. Six out of the 102 pediatric patients weighing more than 40 kg reached adult exposure levels with a 7 mg daily dose. Pharmacokinetic modelling predicts that if these patients would have received 14mg daily, their exposure would still have been within the range of exposures seen in adults treated with 14 mg daily. There is limited experience in pediatric patients with body weight below 40 kg.

Median $t_{1/2z}$ was approximately 20 days. Steady state is estimated to be reached approximately after 3 months.

- **Geriatrics**

The pharmacokinetics in patients aged 65 and over has not been studied. NAT-TERIFLUNOMIDE should be used with caution in patients aged 65 years and over.

- **Sex**

No dosage adjustment is necessary based on body weight and gender. In a population pharmacokinetic analysis, body weight and gender had a limited impact on teriflunomide pharmacokinetics ($\leq 35\%$ increase in mean steady-state AUC_{0-24}).

- **Hepatic Insufficiency**

Mild and moderate hepatic impairment had no impact on the pharmacokinetics of teriflunomide. Therefore, no dose adjustment is anticipated in mild and moderate hepatic impaired patients. The pharmacokinetics of teriflunomide in severe hepatic impairment has not been evaluated. However, teriflunomide is contraindicated in patients with severe hepatic impairment (see 2 CONTRAINDICATIONS, 7 WARNINGS AND PRECAUTIONS, Hepatic/ Biliary/Pancreatic).

- **Renal Insufficiency**

Severe renal impairment had no impact on the pharmacokinetic of teriflunomide. Therefore, no dose adjustment is anticipated in severe renal impaired patients (7 WARNINGS AND PRECAUTIONS, Renal). Patients with severe renal impairment undergoing dialysis were not evaluated. Teriflunomide is not recommended in this population.

- **Patients with early RRMS**

TOPIC was a double-blind, placebo-controlled study that evaluated once daily doses of teriflunomide 7 mg and 14 mg for up to 108 weeks. Patients were required to have had a first clinical event consistent with acute demyelination, which occurred within 90 days of randomization, with two or more T2 lesions of at least 3 mm diameter that were characteristic of multiple sclerosis. A total of 618 patients were randomized to receive 7 mg (n=205) or 14 mg (n=216) of teriflunomide or placebo (n=197). Patients had a mean age of 32 years, EDSS at baseline

of 1.7, and mean disease duration of two months. The primary endpoint was time to a second clinical episode (relapse). The risk of a second clinical attack over two years was statistically significantly less in the teriflunomide 14 mg treatment group compared to the placebo group. The impact of early treatment with teriflunomide on the long term evolution of the disease in this patient population is not known. Adverse events in this study were quantitatively and qualitatively similar to those reported in the clinical trials with patients diagnosed with more advanced RRMS (see 7 WARNINGS AND PRECAUTIONS, 8 ADVERSE REACTIONS).

11 STORAGE, STABILITY AND DISPOSAL

Store at 15°C to 30°C.

For blister pack, remove tablet only when ready to use.

For bottle container, discard after 90 days once opened.

NAT-TERIFLUNOMIDE must be kept out of the reach and sight of children.

PART II: SCIENTIFIC INFORMATION


13 PHARMACEUTICAL INFORMATION

Drug Substance

Proper name: teriflunomide

Chemical name: (Z)-2-Cyano-3-hydroxy-but-2-enoic acid-(4-trifluoromethylphenyl)-amide

Molecular formula and molecular mass: C₁₂H₉F₃N₂O₂ & 270.21



Structural formula:

Physicochemical properties: white to almost white powder that is sparingly soluble in Tetrahydrofuran, soluble in dimethylformamide and slightly soluble in methanol, and insoluble in water.

14 CLINICAL TRIALS

The efficacy of teriflunomide was established in two Phase 3, placebo-controlled studies in patients with relapsing remitting MS.

14.1 Clinical Trials by Indication

Treatment Of Patients with Relapsing Remitting Multiple Sclerosis (RRMS)

STUDY 1

TEMSO: Teriflunomide Multiple Sclerosis Oral trial was a double-blind, placebo-controlled study that evaluated once daily doses of teriflunomide 7 mg and 14 mg primarily in patients with relapsing remitting multiple sclerosis (RRMS) over 108 weeks.

Study demographics and trial design

Table 4 - Summary of patient demographics in TEMSO trial

Study	Trial design	Dosage, route of administration and duration	Randomized study subjects (n=number)	Mean age (range)	Gender
TEMSO	Randomized, double-blind, placebo-controlled, parallel-group	Teriflunomide 7 mg or 14 mg, or placebo, once daily for 108 weeks	<ul style="list-style-type: none">• Teriflunomide 14 mg: n= 359• Teriflunomide 7 mg: n=366• Placebo: n= 363	37.9 (18-55)	F: 72.2% M: 27.8%

A total of 1088 patients with RMS were randomized to receive 7 mg (n=366) or 14 mg (n=359) of

teriflunomide or placebo (n=363).

At entry, patients had an Expanded Disability Status Scale (EDSS) score ≤ 5.5 . The median age of the study population was 38 years, the median disease duration was 6.83 years, and the median EDSS at baseline was 2.50. A total of 91.4% had relapsing remitting MS (RRMS) and 8.6% had a progressive form of MS with relapses. The median time on treatment was 756 days for placebo and for teriflunomide 14 mg.

All patients had a definite diagnosis of MS exhibiting a relapsing clinical course, with or without progression, and experienced at least 1 relapse over the year preceding the trial or at least 2 relapses over the 2 years preceding the trial. Subjects had not received interferon-beta for at least 4 months or any other preventive MS medications for at least 6 months before entering the study, nor were these medications permitted during the study. Neurological evaluations were performed at screening, every 12 weeks until week 108 and at unscheduled visits for suspected relapse. MRI was performed at screening, weeks, 24, 48, 72, and 108.

The primary endpoint was the annualized relapse rate (ARR). The key secondary efficacy variable was confirmed progression of disability for at least 12 weeks. The key prespecified MRI endpoint was total lesion volume (defined as sum of T2 and hypointense T1 lesion volume in mL).

Study Results

The ARR was significantly reduced in patients treated with 14 mg of teriflunomide compared to patients who received placebo (ARR: 0.369; $p=0.0005$ in the 14 mg groups) (**Table 5**).

The risk of disability progression sustained for 12 weeks (as measured by at least a 1-point increase from baseline EDSS ≤ 5.5 or a 0.5 point increase for those with a baseline EDSS > 5.5) was statistically significantly reduced only in the teriflunomide 14 mg group compared to placebo (**Table 5 and Figure 1**). The estimated percentage of patients with a 12-week sustained disability progression at Week 108 was 27.3%, and 20.2% in the placebo and the 14 mg teriflunomide groups, respectively.

The effect of teriflunomide on several magnetic resonance imaging (MRI) variables including the total lesion volume of T2 and hypointense T1 lesions was assessed. The change in total lesion volume from baseline was lower in the 14 mg group than in the placebo group. Patients in the teriflunomide group had fewer gadolinium-enhancing lesions per T1-weighted scan than those in the placebo group (**Table 5**).

The results for this study are shown in **Table 5** and **Figure 1**:

Table 5 – Clinical and MRI Results of TEMSO Study


Primary Endpoints	Teriflunomide 14 mg N=358	Placebo N=363
Clinical Endpoints		
Annualized relapse rate (primary endpoint)	0.369 ($p = 0.0005$)	0.539
Relative risk reduction	31.5%	

Primary Endpoints	Teriflunomide 14 mg N=358	Placebo N=363
Percent disability progression at week 108 ¹	20.2%	27.3%
Hazard ratio	0.70	
Relative risk reduction	30%	
Percent of patients remaining relapse-free at week 108 ¹	56.5%	45.6%
MRI Endpoints		
Median change from baseline in Total lesion volume ² (mL) at week 108	0.345	1.127
Percent change relative to placebo	69%	
Mean number of Gd-enhancing T1-lesions per scan	0.261	1.331
Relative reduction	80%	

¹Values derived from Kaplan-Meier estimates

²Total lesion volume: sum of T2 and hypointense T1 lesion volume in mL

Figure 1 - Kaplan-Meier plot of time to disability progression sustained for 12 weeks - ITT population (Study 1)



STUDY 2

TOWER: Teriflunomide Oral in People With Relapsing Remitting Multiple Sclerosis was a double-blind, placebo-controlled study that evaluated once daily doses of teriflunomide 7 mg and 14 mg in patients with relapsing remitting multiple sclerosis (RRMS) with mean treatment duration of approximately 18 months.

Study demographics and trial design

Table 6 - Summary of patient demographics in TOWER trial

Study	Trial design	Dosage, route of administration and duration	Randomized study subjects (n=number)	Mean age (range)	Gender
TOWER	Randomized, double-blind, parallel group, placebo- controlled study	Teriflunomide 7 mg or 14 mg, or placebo, once daily, up to a fixed end for all patients 48 weeks after the last patient randomized	<ul style="list-style-type: none">• Teriflunomide 14 mg: n= 372• Teriflunomide 7 mg: n=408• Placebo: n=389	37.9 (18-56)	F: 71.1% M: 28.9%

All patients had a definite diagnosis of MS exhibiting a relapsing clinical course, with or without progression, and experienced at least 1 relapse over the year preceding the trial or at least 2 relapses over the 2 years preceding the trial. Subjects had not received interferon-beta or any other preventive MS medications for at least 3 months before entering the study, nor were these medications permitted during the study.

Neurological evaluations were performed at screening, every 12 weeks until completion and at unscheduled visits for suspected relapse.

The primary endpoint was the annualized relapse rate (ARR). The key secondary objective was to assess the effect of the two doses of teriflunomide in comparison to placebo, on disability progression.

A total of 1169 patients were randomized to receive 7 mg (n=408) or 14 mg (n=372) of teriflunomide or placebo (n=389). The median age was 38 years and the study population was primarily Caucasian (82.1%) and Asian/Oriental (14.5%). The median time since first diagnosis of MS was 6.25 years, a majority of the patients had relapsing remitting MS (97.5%), and the median number of relapses within the past one year was 1.0. Median EDSS at baseline was 2.50.

Study Results

The ARR was significantly reduced in patients treated with 14 mg of teriflunomide compared to patients who received placebo (ARR: 0.319; p=0.0001 in the 14 mg groups) (**Table 7**).


The risk of disability progression sustained for 12 weeks (as measured by at least a 1-point increase from baseline EDSS \leq 5.5 or a 0.5 point increase for those with a baseline EDSS $>$ 5.5) was statistically significantly reduced only in the teriflunomide 14 mg group compared to placebo (**Table 7** and **Figure 2**). The estimated percentage of patients with a 12-week sustained disability progression at Week 108 was 19.7%, and 15.8% in the placebo and the 14 mg teriflunomide groups, respectively.

Table 7 Clinical Results of TOWER Study

	Teriflunomide 14 mg N=370	Placebo N=388
Annualized relapse rate (primary endpoint)	0.319 (p = 0.0001)	0.501
Relative risk reduction	36.3%	
Percent of patients remaining relapse-free at week 108 ¹	57.1%	46.8%
Percent disability progression at week 108 ¹	15.8%	19.7%
Hazard ratio	0.69	
Relative risk reduction	31%	

¹ Values derived from Kaplan-Meier estimates

Figure 2 Kaplan-Meier plot of time to disability progression sustained for 12 weeks - ITT population (Study 2)



14.3 Comparative Bioavailability Studies

A double blinded, randomized, single-dose, two-treatment, one-period, parallel design, oral comparative bioavailability study of NAT-TERIFLUNOMIDE 14 mg tablet (Natco Pharma (Canada) Inc.) and AUBAGIO® 14 mg tablet (Sanofi Genzyme, a division of sanofi-aventis Canada Inc) was conducted in 72 healthy, adult, male subjects under fasting conditions. Comparative bioavailability data from 72 subjects that were included in the statistical analysis are presented in the following table.

SUMMARY TABLE OF THE COMPARATIVE BIOAVAILABILITY DATA

Teriflunomide (1 x 14 mg) Geometric Mean Arithmetic Mean (% CV)				
Parameter	Test ¹	Reference ²	% Ratio of Geometric Means	90% Confidence Interval
AUC _{0-72h} (ng·h/mL)	103030.9 103646.3 (11.12)	107405.3 108271.79 (12.83)	95.9	91.5 - 100.7
C _{max} (ng/mL)	2145.1 2163.2 (12.85)	2297.8 2322.9 (14.90)	93.4	88.3 - 98.7
T _{max} ³ (h)	2.000 (0.50-36.00)	1.500 (0.50 - 4.00)		

¹ NAT-TERIFLUNOMIDE (teriflunomide) tablets, 14 mg (Natco Pharma (Canada) Inc.)

² AUBAGIO® (teriflunomide) tablets, 14 mg (Genzyme Canada, a division of sanofi-aventis Canada Inc.)

³ Expressed as the median (range) only.

Due to the long elimination half-life of teriflunomide, AUC_i and T_{1/2} could not be accurately calculated from the data obtained in this study.

15 MICROBIOLOGY

No microbiological information is required for this drug product.

16 NON-CLINICAL TOXICOLOGY

Genotoxicity: Teriflunomide was not clastogenic in vivo in the 3 species tested: mouse (micronucleus test), Chinese hamster (chromosome aberration test), and rat (repeat-dose chromosome aberration test). Positive results were seen in an in vitro chromosome aberration test in human lymphocytes after 3-hour treatment both with and without metabolic activation. Supplementation with uridine (to supplement the pyrimidine pool) reduced the cytotoxicity and the magnitude of the clastogenic effect.

The positive response is considered to be an indirect effect due to the pharmacologic mechanism of action of nucleotide pool imbalance resulting from DHODH inhibition.

4-Trifluoromethylaniline (4-TFMA), a minor metabolite of teriflunomide, was clastogenic in the in vitro chromosome aberration test in Chinese hamster cells. 4-TFMA was not clastogenic in vivo in the 2 species tested: mouse (micronucleus test) and Chinese hamsters (chromosome aberration test). Equivocal results were seen in the unscheduled DNA synthesis (UDS) test in rat liver.

Mutagenesis: Teriflunomide was not mutagenic, in the in vitro bacterial reverse mutation (Ames) and hypoxanthine-guanine-phosphoribosyl transferase (HPRT) tests. Teriflunomide was positive in an in vitro chromosomal aberration assay in human lymphocytes, with and without metabolic activation. Addition of uridine (to supplement the pyrimidine pool) reduced the magnitude of the clastogenic effect; however, teriflunomide was positive in the in vitro chromosomal aberration assay, even in the presence of uridine.

4-Trifluoromethylaniline (4-TFMA), a minor metabolite of teriflunomide, was mutagenic in the Ames and HPRT tests. 4-TFMA was positive in the in vitro chromosomal aberration assay in mammalian cells but negative in in vivo micronucleus and chromosomal aberration assays.

Carcinogenicity: No evidence of carcinogenicity was observed in a 2-year bioassay in rats at oral doses of teriflunomide up to the maximally tolerated dose of 4 mg/kg/day (approximately 1/2 the maximum human teriflunomide systemic exposure based on AUC₀₋₂₄). Moreover, no evidence of carcinogenicity was observed in a 2-year bioassay in mice at oral doses of teriflunomide up to the maximally tolerated dose of 12 mg/kg/day (approximately 5-6 times the maximum human teriflunomide systemic exposure based on AUC₀₋₂₄).

Reproductive and Developmental Toxicology: Teratogenicity: In studies conducted in pregnant rats and rabbits, oral administration of teriflunomide resulted in embryo lethality, reduced fetal body weight, and/or malformations. In rats, exposure at the no-observed-effect-level (1.0 mg/kg/day) for teratogenicity and embryo lethality was less than the human exposure at 14 mg/day on a mg/kg basis. Primary malformations in rats were microphthalmia or anophthalmia; accompanied by aplasia lentis and decreased orbit size; hydrocephalus; edematous fetus; hematocyst on parietal bone; brachygnathia inferior; bent tarsal region of the hindpaw; fragmented, dysplastic and fused skull bones; multiple anomalies of the vertebral column; and alterations of ribs and pectoral girdle. In rabbits, exposure at the no-observed-effect-level (1.0 mg/kg/day) was also less than the human exposure at 14 mg/day on a mg/kg basis. Malformations of the forelimbs (short and misshapen ulna, absent radius, brachydactyly); absence of kidney, adrenal, and ureter; cleft lip and palate; growth retardation; hyperflexion of the forepaws; malpositioned branch of the carotid; anomalies of the lung lobes and sternbrae; and delayed ossification of several bones were observed.

In a study where teriflunomide was administered to pregnant rats during gestation and lactation, teriflunomide did not affect sexual maturation, learning, memory, motor activity, startle response, reproductive ability, estrous cycles, mating behavior, fertility and fecundity, or early embryonic development. Adverse effects observed in the offspring at 0.3 mg/kg/day included limb defects and impaired coat growth sometimes associated with skin discoloration. Corneal opacity, eye discharge, and negative pupillary reflex occurred in a few pups. Mean fetal weight per litter was slightly decreased. Effects on coat growth resolved but limb defects persisted in a few pups after weaning. The no-observed-effect-level in the offspring was 0.10 mg/kg/day. Of importance, similar adverse findings were not seen in an exploratory study where teriflunomide was administered at 1.0 mg/kg/day during the gestation period and not during lactation to avoid transfer of teriflunomide in the milk. Under those conditions, the no-observed-effect-level in the offspring was 1.0 mg/kg/day.

Impairment of fertility: In separate male and female fertility studies, oral administration of teriflunomide to rats prior to and during mating (both sexes), and continuing to Day 6 of gestation (females) had no effect on fertility up to the highest doses tested (10 and 8.6 mg/kg/day in males and females, respectively), which is approximately 7 and 6 times the recommended human dose (RHD) on a mg/m² basis, respectively. However, effects on the fetus were observed in the female fertility study that consisted of embryoletality and isolated malformations at doses of 2.6 mg/kg/day and above and decreased fetal body weight down to the lowest dose tested of 0.84 mg/kg/d. In males, a slight decrease in epididymal sperm count (-12.5%) was observed at the highest dose (10 mg/kg/day) with no microscopic correlate in the testes or epididymides.

17 SUPPORTING PRODUCT MONOGRAPHS

^{Pr}AUBAGIO® Teriflunomide tablets, 14 mg, submission control 270681, Product Monograph, Sanofi Genzyme, a division of sanofi-aventis Canada Inc. (June 23, 2023)

PATIENT MEDICATION INFORMATION

READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE

Pr **NAT-TERIFLUNOMIDE**

Teriflunomide tablets

Read this carefully before you start taking **NAT-TERIFLUNOMIDE** and each time you get a refill. This leaflet is a summary and will not tell you everything about this drug. Talk to your healthcare professional about your medical condition and treatment and ask if there is any new information about **NAT-TERIFLUNOMIDE**.

Serious Warnings and Precautions

LIVER DISORDER

NAT-TERIFLUNOMIDE may cause liver disorders. Severe liver injury including fatal liver failure occurred rarely in patients treated with teriflunomide. The risk for severe liver disorder may be increased if you take NAT-TERIFLUNOMIDE when you already have liver disease or if you are taking other drugs that affect the liver.

Your healthcare professional should do blood tests to check your liver function:

- within 6 months before you start taking NAT-TERIFLUNOMIDE.
- every month, for at least 6 months after you start taking NAT-TERIFLUNOMIDE.

Call your healthcare professional right away if you experience any symptoms of liver disorder (see the **Serious side effects and what to do about them** table below for a list of symptoms).

BIRTH CONTROL, PREGNANCY and RISK OF BIRTH DEFECTS

Do not take NAT-TERIFLUNOMIDE if you are pregnant. If used during pregnancy, NAT-TERIFLUNOMIDE may cause major birth defects and even death to your baby. Pregnancy must be avoided by using effective birth control when a man or woman is on NAT-TERIFLUNOMIDE. Continue birth control for two years after you stop taking NAT-TERIFLUNOMIDE to make sure your blood levels of teriflunomide are low enough. Your healthcare professional can prescribe a medicine to help lower your blood levels of teriflunomide more quickly. Your healthcare professional can inform you when it is safe to get pregnant or to father a child.

If you are a **woman** of childbearing age, you should have a pregnancy test before you start taking NAT-TERIFLUNOMIDE. If you become pregnant, are late starting your period or have any reason to suspect pregnancy while taking NAT-TERIFLUNOMIDE or within 2 years after stopping it, tell your healthcare professional right away.

What is NAT-TERIFLUNOMIDE used for?

NAT-TERIFLUNOMIDE is used to treat adult patients with relapsing remitting multiple sclerosis (RRMS).

How does NAT-TERIFLUNOMIDE work?

NAT-TERIFLUNOMIDE can alter the way the body's immune system works. NAT-TERIFLUNOMIDE does not cure RRMS, but it can help decrease the number of attacks (relapses) that occur. NAT-

TERIFLUNOMIDE can help slow the build-up of physical problems (disability progression) that RRMS causes.

What are the ingredients in NAT-TERIFLUNOMIDE?

Medicinal ingredients: teriflunomide

Non-medicinal ingredients: Lactose monohydrate, pregelatinized starch, hydroxypropylcellulose, sodium starch glycolate, colloidal silicon dioxide, magnesium stearate, hypromellose, titanium dioxide, talc, macrogol, and indigo carmine aluminum lake.

NAT-TERIFLUNOMIDE comes in the following dosage forms:

Tablet; 14 mg

Do not use NAT-TERIFLUNOMIDE if:

- you are allergic to teriflunomide, leflunomide or to any of the other ingredients in the formulation
- you are taking a drug for rheumatoid arthritis with the medicinal ingredient leflunomide
- you have severe liver problems
- you are suffering from a serious infection
- you are pregnant, suspect you may be pregnant or plan to get pregnant
- you are a woman of childbearing potential not using reliable methods of birth control
- you are of childbearing age, until it is confirmed with a pregnancy test that you are not pregnant.
- you have low platelets, or low white blood cell counts, or uncontrolled infection. Low white blood cell counts may be caused by other things that affect the immune system such as:
 - immunodeficiency syndrome or AIDS
 - weakened bone marrow function or transplantation
 - treatments that can suppress the immune system such as
 - drugs used to treat cancer
 - other drugs used to treat MS

To help avoid side effects and ensure proper use, talk to your healthcare professional before you take NAT-TERIFLUNOMIDE. Talk about any health conditions or problems you may have, including if you:

- have liver problems.
- have high blood pressure
- have a fever or infection, or you are unable to fight infections
- have low protein levels in your blood
- have or have ever had blood or bone marrow problems
- have kidney problems
- have or have ever had tuberculosis
- have diabetes
- are older than 60 years
- are breastfeeding or plan to breastfeed. You and your healthcare professional should decide if you will take NAT-TERIFLUNOMIDE or breastfeed. You should not do both at the same time.
- have a condition that affects the skin or nails called psoriasis
- have an allergy to lactose or a rare hereditary problem of galactose intolerance, total lactose deficiency or glucose-galactose malabsorption. NAT-TERIFLUNOMIDE contains lactose.

- are going to receive a vaccine. You should not receive a “live attenuated vaccine” during treatment with NAT-TERIFLUNOMIDE. Talk to your healthcare professional before receiving any vaccinations during or after treatment.

Other warnings you should know about:

Pregnancy: NAT-TERIFLUNOMIDE may harm your unborn baby. Before you start treatment with NAT-TERIFLUNOMIDE, your healthcare professional may require you to do a pregnancy test to make sure you are not pregnant. You must use a reliable form of birth control while taking NAT-TERIFLUNOMIDE. Do not become pregnant during treatment.

Teriflunomide Enhanced Pharmacovigilance Pregnancy Active Surveillance Program: If you become pregnant or suspect you may be pregnant while taking NAT-TERIFLUNOMIDE, or become pregnant within two years after you stop taking NAT-TERIFLUNOMIDE, contact your healthcare professional right away. A Teriflunomide Enhanced Pharmacovigilance Pregnancy Active Surveillance Program has been established to collect information about the effect of teriflunomide exposure during pregnancy. Your doctor can enroll you in the Enhanced Pharmacovigilance Pregnancy Active Surveillance Program, or you may enroll yourself in the Enhanced Pharmacovigilance Pregnancy Active Surveillance Program by calling 1-800-296-9329. Program details and educational materials can be found at the following website – www.natcopharma.ca.

Use in Males: If your partner can get pregnant, make sure to use a reliable form of birth control when you are taking NAT-TERIFLUNOMIDE. If you wish to father a child or donate sperm, talk to your healthcare professional about stopping your treatment.

Blood Tests: Your healthcare professional should do blood tests before starting treatment with NAT-TERIFLUNOMIDE and while you are taking it. These tests will monitor:

- blood pressure
- complete blood cell count
- liver enzyme levels

NAT-TERIFLUNOMIDE may cause your test results to look abnormal. Your healthcare professional will interpret the results.

Interstitial Lung Disease (ILD): A condition called ILD has been reported with teriflunomide. If you have a history of ILD, you are at higher risk of developing ILD again. If you already have ILD, NAT-TERIFLUNOMIDE may worsen the symptoms. ILD can be a fatal disorder and can happen at any time during your treatment. Talk to your healthcare professional right away if you experience:

- persistent cough
- shortness of breath with or without fever

NAT-TERIFLUNOMIDE can cause serious side effects, including:

- Pancreatitis (inflammation of the pancreas)
- Peripheral Neuropathy (damage to nerves)
- Severe skin reactions such as Stevens - Johnson Syndrome (SJS), Toxic Epidermal Necrolysis (TEN) and Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)

See the **Serious side effects and what to do about them** table below for more information on these and other serious side effects.

Accelerated Elimination Procedure: It can take 8 months to 2 years to fully remove teriflunomide from your system. If you need to stop taking NAT-TERIFLUNOMIDE, your healthcare professional may talk to you about undergoing an accelerated elimination procedure to remove teriflunomide from your body faster.

Tell your healthcare professional about all the medicines you take, including any drugs, vitamins, minerals, natural supplements or alternative medicines.

The following may interact with NAT-TERIFLUNOMIDE:

- leflunomide, a medication for rheumatoid arthritis
- medicines that could raise your chance of getting infections, such as medicines to treat cancer or to control your immune system. **Ask your healthcare professional or pharmacist for a list of these medicines if you are not sure**
- warfarin
- medicines used to treat diabetes, such as: repaglinide, pioglitazone, rosiglitazone, nateglinide
- oral contraceptives
- some medicines used to treat infections such as: cefaclor, penicillin G, ciprofloxacin, rifampin, zidovudine
- medicines used to lower blood cholesterol, such as: rosuvastatin, atorvastatin, simvastatin, pravastatin
- anti-inflammatory drugs, such as: indomethacin, ketoprofen, sulfasalazine
- diuretics (water losing pills), such as: furosemide
- some medicines to treat cancer such as: paclitaxel, methotrexate, mitoxantrone, topotecan, daunorubicin, doxorubicin
- duloxetine (anti-depressant); theophylline (asthma medicine); cimetidine (stomach acid medicine); tizanidine (muscle relaxant medicine)
- avoid drinking alcohol while taking NAT-TERIFLUNOMIDE as it may cause liver problems.
- other medicines that can potentially harm the liver

How to take NAT-TERIFLUNOMIDE:

- Follow your healthcare professional's instructions carefully. Do not take more than the recommended dose.
- Take NAT-TERIFLUNOMIDE orally (by mouth) with or without food.
- Do not stop taking NAT-TERIFLUNOMIDE without talking with your healthcare professional first.

Usual dose:

1 tablet a day.

Overdose:

If you think you, or a person you are caring for, have taken too much **NAT-TERIFLUNOMIDE**, contact a healthcare professional, hospital emergency department, or regional poison control centre

immediately, even if there are no symptoms.

Missed Dose:

If you miss a dose, just take your next dose as planned. Do not take a double dose to make up for a forgotten tablet.

What are possible side effects from using NAT-TERIFLUNOMIDE?

These are not all the possible side effects you may have when taking NAT-TERIFLUNOMIDE. If you experience any side effects not listed here, tell your healthcare professional.:

- diarrhea, nausea, flu or sinus infection, upset stomach, abdominal pain
- rash
- abnormal liver tests
- hair thinning or loss
- cold sores
- toothache
- shortness of breath
- frequent urination
- having your period for longer than 7 days
- sore muscles
- weight loss

Serious side effects and what to do about them			
Symptom / effect	Talk to your healthcare professional		Stop taking drug and get immediate medical help
	Only if severe	In all cases	
COMMON			
Decreased White Blood Cells: infections, fatigue, fever, aches, pains and flu-like symptoms		√	
Hypertension (high blood pressure): shortness of breath, fatigue, dizziness or fainting, chest pain or pressure, swelling in your ankles and legs, bluish colour to your lips and skin, racing pulse or heart palpitations		√	
Liver Disorder: yellowing of the skin or eyes, dark urine and pale stools, abdominal pain, nausea, vomiting, loss of appetite.			√
UNCOMMON			

Serious side effects and what to do about them			
Symptom / effect	Talk to your healthcare professional		Stop taking drug and get immediate medical help
	Only if severe	In all cases	
Decreased Platelets: bruising or bleeding for longer than usual if you hurt yourself, fatigue and weakness		√	
Severe Heart Problems: pressure or squeezing pain between the shoulder blades, in the chest, jaw, left arm or upper abdomen, shortness of breath, dizziness, fatigue, light-headedness, clammy skin, sweating, indigestion, anxiety, feeling faint and possible irregular heartbeat. Deaths due to heart-related issues have occurred in patients treated with teriflunomide.			√
Peripheral Neuropathy/ Carpal tunnel syndrome: numbness or tingling of hands or feet		√	
RARE			
Interstitial Lung Disease (disease that inflames or scars lung tissue): shortness of breath when resting that gets worse with exertion, trouble breathing, lasting cough		√	
UNKNOWN			
Allergic Reaction: difficulty swallowing or breathing, wheezing; drop in blood pressure; feeling sick to your stomach and throwing up; hives or rash; swelling of the face, lips, tongue or throat			√
Colitis (chronic digestive disease): diarrhea with blood or pus, abdominal pain, cramping, rectal pain or bleeding, weight loss, fatigue		√	
Pancreatitis (inflammation of the pancreas): upper abdominal pain,			

Serious side effects and what to do about them			
Symptom / effect	Talk to your healthcare professional		Stop taking drug and get immediate medical help
	Only if severe	In all cases	
fever, fast heart beat, nausea, vomiting, tenderness when touching the abdomen			√
Psoriasis (chronic skin disease on the skin or nails): red patches of skin covered with thick, silvery scales, dry cracked skin that may bleed, itching, burning or soreness, swollen and stiff joints		√	
Severe Skin Reactions: Fever, severe rash, swollen lymph glands, flu-like feeling, blisters and peeling skin that may start in and around the mouth, nose, eyes or genitals and spread to other areas of the body, yellow skin or eyes, shortness of breath, dry cough, chest pain or discomfort, feeling thirsty, urinating less often, less urine			√

If you have a troublesome symptom or side effect that is not listed here or becomes bad enough to interfere with your daily activities, tell your healthcare professional.

Reporting Side Effects

You can report any suspected side effects associated with the use of health products to Health Canada by:

- Visiting the Web page on Adverse Reaction Reporting (<https://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada.html>) for information on how to report online, by mail or by fax; or
- Calling toll-free at 1-866-234-2345.

NOTE: Contact your health professional if you need information about how to manage your side effects. The Canada Vigilance Program does not provide medical advice.

Storage:

Store NAT-TERIFLUNOMIDE between 15°C to 30°C.

For blister pack, remove tablet only when ready to use.

Once the bottle is opened, the tablets must be used within 90 days.

Keep out of reach and sight of children.

If you want more information about NAT-TERIFLUNOMIDE:

- Talk to your healthcare professional
- Find the full product monograph that is prepared for healthcare professionals and includes this Patient Medication Information by visiting the Health Canada website: (<https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/drug-product-database.html>); the manufacturer's website www.natcopharma.ca, or by calling 1-800-296-9329.

This leaflet was prepared by Natco Pharma (Canada) Inc. Mississauga, Ontario L5N 1P7

Last Revised October 27, 2023